Diversion of Buprenorphine/Naloxone Coformulated Tablets in a Region with High Prescribing Prevalence
暂无分享,去创建一个
Edward W Boyer | Andrew A Monte | E. Boyer | A. Monte | Bonnie B Wilford | Todd Mandell | Joseph Tennyson | Todd W Mandell | B. B. Wilford | J. Tennyson
[1] P. O'Connor,et al. Clinical practice. Office-based treatment of opioid-dependent patients. , 2002, The New England journal of medicine.
[2] M. Stitzer,et al. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. , 1995, Drug and alcohol dependence.
[3] K. Preston,et al. Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.
[4] A. Cowan,et al. Buprenorphine: a unique drug with complex pharmacology. , 2004, Current neuropharmacology.
[5] E. Vuori,et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. , 2007, Drug and alcohol dependence.
[6] M. Carrieri,et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. , 2008, Addiction.
[7] G. Badger,et al. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. , 2001, Addiction.
[8] Katherine B. Morton,et al. Results from the 2008 National Survey on Drug Use and Health: National findings , 2009 .
[9] J. Jaffe,et al. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate‐day administration and abrupt withdrawal , 1990, Clinical pharmacology and therapeutics.
[10] E. Boyer,et al. Adverse Effects in Children After Unintentional Buprenorphine Exposure , 2006, Pediatrics.
[11] S. Strathdee,et al. HIV, Hepatitis C, and Hepatitis B Infections and Associated Risk Behavior in Injection Drug Users, Kabul, Afghanistan , 2007, Emerging infectious diseases.
[12] R. Dart,et al. The underrecognized toll of prescription opioid abuse on young children. , 2009, Annals of emergency medicine.
[13] David E. Smith,et al. Buprenorphine: blending practice and research. , 2002, Journal of substance abuse treatment.
[14] W. H. Morse,et al. Respiratory effects of opioid full and partial agonists in rhesus monkeys. , 1996, The Journal of pharmacology and experimental therapeutics.
[15] Thomas R Kosten,et al. Combating opiate dependence: a comparison among the available pharmacological options , 2004, Expert opinion on pharmacotherapy.
[16] Declan T. Barry,et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. , 2008, Journal of substance abuse treatment.
[17] R. Ferner,et al. Office-based treatment of opioid-dependent patients. , 2003, The New England journal of medicine.
[18] M. Carrieri,et al. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). , 2007, The International journal on drug policy.
[19] J. Kaldor,et al. Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia. , 2007, Drug and alcohol dependence.
[20] G. Woody,et al. Abuse of Buprenorphine in the United States , 2007, Journal of addictive diseases.
[21] N. Horton,et al. Overdose after detoxification: a prospective study. , 2007, Drug and alcohol dependence.
[22] B. Mégarbane,et al. Does High-Dose Buprenorphine Cause Respiratory Depression? , 2006, Toxicological reviews.
[23] A. Muñoz,et al. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. , 2005, The journal of pain : official journal of the American Pain Society.